This article from the December issue of Nature Reviews Drug Discovery outlines the importance of a biomarker strategy for personalized medicine in oncology. However, the ideas presented in this piece are easily generalized to drug development in other therapeutic areas and offer some good reminders of the risks (expensive up-front costs) and rewards (better safety/efficacy profile for the drug, premium pricing on the market) associated with biomarkers and companion diagnostics.
